Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

NCT00101907 ↗

Phase 1 Terminated 41 enrolled Amgen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.

Timeline

Start: 2004-12
Primary completion: 2007-06
Completion: 2008-04

Publications

Background Burris H, Stephenson J, Otterson GA, Stein M, McGreivy J, Sun YN, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol. 2011;2011:853931. doi: 10.1155/2011/853931. Epub 2011 Apr 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Panitumumab	Monoclonal antibody	9 mg/kg	Intravenous
Subject	motesanib	Small molecule	50 mg	Oral
Subject	motesanib	Small molecule	75 mg	Oral
Subject	motesanib	Small molecule	100 mg	Oral
Subject	motesanib	Small molecule	125 mg	Oral
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1250 mg/m2	Intravenous

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications